Key facts
- It has raised $42.7M; the latest was Early Stage VC ($28.7M) in Feb 2026.
- Notable investors include Qiming Venture Partners, Yonghua Capital, CMG SDIC Fund, GSR United Capital, CNPC Kunlun Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Matwings Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Matwings Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Matwings Technology
Developer of an artificial intelligence-based general protein design platform intended to provide computational chemistry for innovative drug molecular design. The company offers data-driven modeling capabilities, iterative computational refinement, experimentally anchored validation workflows, diverse engineering methodologies that adjust stability, activity, and specificity, and adaptable project support across biotechnology, diagnostics, nutrition, therapeutic development, and bio manufacturing fields, enabling engineered molecular components into their development pipelines.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- matwings.com/
- Ownership
- Privately Held (backing)
Matwings Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Matwings Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Matwings Technology in its N-PORT filings yet. We sweep new filings monthly.